ZN-c3 for Solid Tumors

Phase 1

Recruiting

Research Sponsored by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through completion, average of 1 year

Awards & highlights

No Placebo-Only Group

Summary

This trial tests a new drug called ZN-c3 on its own. It focuses on patients with specific advanced cancers that have DNA damage. The drug aims to stop cancer cell growth by targeting these damaged cells.

Eligible Conditions

Solid Tumors

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ through completion, average of 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~through completion, average of 1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and through completion, average of 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Dose Escalation

Dose Expansion

Secondary study objectives

Dose Escalation, Food Effect cohort & Dose Expansion

Dose Escalation, Food Effect cohort and Dose Expansion

Food Effect Cohort

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups

Experimental Treatment

Group I: Single Agent Food Effect CohortExperimental Treatment1 Intervention

Subjects with solid tumors with advanced or metastatic disease who are refractory or ineligible to standard therapy(ies) or for whom no standard therapy is available. This cohort will give subjects the option to continue treatment after PK assessments are completed.

Group II: Single Agent Dose ExpansionExperimental Treatment1 Intervention

Subjects with histologically confirmed recurrent or persistent USC who have had treatment with at least 1 prior platinum-based chemotherapy regimen for management of advanced or metastatic USC and subjects with locally advanced or metastatic malignancy with one or more relevant biomarkers related to DNA damage pathways.

Group III: Single Agent Dose EscalationExperimental Treatment1 Intervention

Subjects with solid tumors with advanced or metastatic disease who are refractory or ineligible to standard therapy(ies) or for whom no standard therapy is available.

Do I qualify?Apply below to find out